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Edited by Horst FeldmannAbstract F-Box proteins (FBPs) are variable adaptor proteins
that earmark protein substrates for ubiquination and destruction
by the proteasome. Through their N-terminal F-box motif, they
couple speciﬁc protein substrates to a catalytic machinery known
as SCF (Skp-1/Cul1/F-Box) E3-ubiquitin ligase. Typical FBPs
bind the speciﬁc substrates in a phosphorylation dependent man-
ner via their C-termini using either leucine rich repeats (LRR) or
tryptophan-aspartic acid (WD40) domains for substrate recogni-
tion. By using a gene trap strategy that selects for genes induced
during programmed cell death, we have isolated the mouse homo-
log of the hypothetical human F-Box protein 33 (FBX33). Here
we identify FBX33 as a component of an SCF E3-ubiquitin li-
gase that targets the multifunctional regulator Y-box binding
protein 1 (YB-1)/dbpB/p50 for polyubiquitination and destruc-
tion by the proteasome. By targeting YB-1 for proteasomal deg-
radation, FBX33 negatively interferes with YB-1 mediated
functions. In contrast to typical FBPs, FBX33 has no C-terminal
LRR or WD40 domains and associates with YB-1 via its N-ter-
minus. The present study conﬁrms the existence of a formerly
hypothetical F-Box protein in living cells and describes one of
its substrates.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis or programmed cell death (PCD) is a genetically
controlled program of cellular self-destruction that is of central
importance for development and cellular homeostasis in all ani-
mals. It is a highly regulated process involving both transcrip-
tional and posttranscriptional mechanisms. To identify genesAbbreviations: AIG30-12-1, apoptosis-induced gene 30-12-1; CSD,
cold shock domain; Cul1, Cullin 1; FBPs, F-Box proteins; FBX33,
F-box protein 33; GST, glutathione S-transferase; HA, haemaggluti-
nin; IL-2, interleukin-2; IL-3, interleukin-3; IRE, iron responsive
element; IRP2, IRE binding protein 2; LRR, leucin rich repeats; mdr-
1, multidrug resistance protein 1; MHC-II, major histocompatibility
complex class II; PCD, programmed cell death; SCF, Skp-1/Cul1/F-
box complex; SKP1, S-phase kinase-associated protein 1; WD40,
tryptophan-aspartic acid domains; YB-1, Y-box binding protein 1
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doi:10.1016/j.febslet.2006.06.023that are induced in cells undergoing apoptosis, we developed a
strategy that combines gene trap mutagenesis with site speciﬁc
recombination (Cre/loxP) [1]. We applied this strategy to the
interleukin-3 (IL-3) dependent hematopoietic precursor cell line
FDCP-1 to recover genes induced in cells undergoing apoptosis
after IL-3 withdrawal [2]. One of these genes, isolated as the
apoptosis inducible gene 30-12-1 (AIG30-12-1), encoded the
mouse homolog of the hypothetical F-Box protein 33 (FBX33)
[3], whose functional analysis is the subject of this paper.
F-Box proteins (FBPs) are variable adaptor proteins that
earmark protein substrates for ubiquitination and destruction
by the proteasome. Through their N-terminal F-box motif,
they couple speciﬁc protein substrates to a catalytic machinery
consisting of the highly conserved proteins Skp1, Cdc53, Cul-
lin 1 (Cul1), and Rbx1/Roc1/Hrt1. This multicomponent com-
plex, known as SCF (Skp-1/Cul1/F-Box) E3-ubiquitin ligase,
recruits two additional enzymes, which assemble (E2-ubiquitin
conjugating enzyme) and activate (E1-ubiquitin activating en-
zyme) multiple ubiquitin molecules at the substrate. As a re-
sult, the poly-ubiquitinated substrate is destroyed by the 26S
proteasome (reviewed in [4–8]). In typical FBPs, the substrate
binding speciﬁcities are encoded in their C-terminus by either
one of two repeat structures, known as LRR (leucine-rich re-
peats) or WD40 (tryptophan-aspartic acid) domains [5,9].
However, atypical F-Box proteins with poorly deﬁned sub-
strate binding regions have also been described [10]. Thus,
based on their C-terminal aminoacid composition, FBPs have
been classiﬁed into (i) FBPs with LRR domains (FBXL), (ii)
FBPs with WD40 domains (FBXW), and (iii) FBPs with
neither LRR nor WD40 domains (F-Box only; FBX)
[9–11].
We show here that the mouse homolog of the hypothetical
FBX33 binds to the cold shock domain (CSD) of the multi-
functional regulator Y-box binding protein 1 (YB-1)/dbpB/
p50 (YB1) via its aminoterminus as part of an SCF-E3 ubiqui-
tin ligase that targets YB-1 for proteasomal degradation.
YB-1 belongs to the family of Y-box proteins and was ini-
tially isolated as a transcription factor binding to the Y-box
of the MHC class II promoter [12]. YB-1 binds the Y-Box
by a 78 aminoacid motif located near its N-terminus, that is
shared among family members [13]. By containing a cold
shock domain, YB-1 also belongs to the most evolutionarily
conserved family of nucleic acid-binding proteins known
among bacteria, plants, and animals [14]. This high degree of
conservation combined with the large number of mammalian
genes containing Y-Box elements in their promoters suggestblished by Elsevier B.V. All rights reserved.
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cesses [15].
YB-1 is overexpressed in a multitude of solid tumors includ-
ing breast, lung, bone, ovarian and colorectal cancers [16–21].
It is a strong inducer of the mdr-1 gene, whose product is
responsible for multi-drug resistance in a variety of cancers
[17,22–24]. Moreover, several cell cycle regulated genes contain
Y-Box elements in their promoters, suggesting that YB-1 plays
a critical role in cell cycle control [25]. Indeed, YB-1 has been
shown recently to upregulate the cell cycle progression genes –
cyclin A and B1 [26]. YB-1 also protects certain cells against
apoptosis. For example, when overexpressed in B-lympho-
cytes, it represses the expression of Fas-ligand, which is a proa-
poptotic cytokine [27]. Conversely, mutational inactivation of
YB-1 in pre B-cells increases their rate of spontaneous apopto-
sis [28].
As a major component of cytoplasmatic messenger ribonu-
cleoprotein particles, YB-1 also controls protein translation
[29,30]. For example, by binding to the 5 0-cap site of the IL-
2 mRNA, YB-1 stabilizes the transcript thus enhancing IL-2
translation [31]. Similarly, YB-1 enhances the translation of
mRNAs with iron responsive elements (IREs) by dislocating
the inhibitory IRE binding protein 2 (IRP2) from these ele-
ments [32]. Finally, YB-1 exhibits exonuclease activity, impli-
cating it in DNA-repair [33].
Taken together, present knowledge suggests that YB-1 is a
multifunctional protein whose expression requires tight con-
trol. As part of this control, we show here that the FBX33 be-
longs to an SCF E3 ubiquitin ligase that targets YB-1 for
ubiquitination and degradation by the proteasome.2. Materials and methods
2.1. Plasmids
Based on a putative full length cDNA sequence assembled from 5 0
and 3 0 RACE products derived from the gene trap insertion site and
from GenBank ESTs, speciﬁc primers were designed to amplify the
AIG30-12-1/FBX33 cDNA from FDCP-1 cells in two steps. In a ﬁrst
step, the C-terminal region encoding the last 276 aminoacids was
ampliﬁed by RT-PCR using BamHI tagged primers and cloned into
the BamHI site of pGem3Zf(+) (Promega) to obtain pGEM-CT. In
a second step, the GC-rich N-terminal regions encoding either aa 1–
286 or 62–286 were ampliﬁed using the Taq High Fidelity/Enhancer
kit (Clontech) and cloned as BamHI/NcoI fragments into pGEM-CT
to obtain pGEM-FL (full length) and pGEM-DN (N-terminus
deleted), respectively. To obtain an F-Box deleted variant of AIG30-
12-1/FBX33 (pGEM-DF), the cDNA sequences upstream and down-
stream of the F-Box encoding aa 1–73 and 114–562, respectively, were
ampliﬁed from pGEM-FL, religated using a NotI site introduced by
PCR and recloned into pGEM. For N-terminal haemagglutinin
(HA)-tagging, the FL, DN and DF cDNAs were subcloned as BamHI
fragments into a pcDNA1 (Invitrogen) vector with sequences encoding
the HA-tag inserted upstream of the polylinker. Finally, the cDNAs
fused to HA tags were subcloned as XhoI/EcoRI fragments into
pcDNA3.1 to obtain the expression vectors HA-FL, HA-DN and
HA-DF. For C-terminal FLAG-tag fusions, the cDNAs were cloned
into pCMVtag4A (Stratagene) after replacing their stop codons with
XhoI sites by PCR. This yielded the expression vectors FLAG-FL,
FLAG-DN and FLAG-DF. The V5- and HA-YB-1 and HA-ubiquitin
expression vectors as well as the YB-1 inducible pALUC reporter plas-
mid have been previously described [34–36].
2.2. MALDI-TOF mass spectrometry
Crude protein lysates of COS7 cells transfected with HA-FL, HA-
DF and pcDNA3.1 expression vectors were immunoprecipitated with
anti-HA antibodies prior to SDS–PAGE. Protein complexes wereseparated on 4–20% polyacrylamide gradient gels (Biorad). Protein
bands that coprecipitated independently of the F-Box were isolated
from Coomassie stained gels and digested with trypsin. The resulting
peptides were analyzed by matrix-assisted laser-desorption/ionization
time-of-ﬂight (MALDI-TOF) mass spectrometry with a Bruker Reﬂex
II instrument. Proteins were identiﬁed by GenBank (NR) and Swiss-
Prot database searches using the ProFound and Mascot software.
2.3. Antibodies
For antibody production the AIG30-12-1/FBX33 CT fragment was
recovered from pGEM-CT and subcloned into pGEX4T1 to obtain
pGEX-CT. pGEX-CT was expressed in the Escherichia coli
BL21(plysS) bacterial strain and glutathione S-transferase (GST) fu-
sion proteins were recovered by glutathione–Sepharose chromatogra-
phy. Rabbit immunization with puriﬁed protein was performed by
Eurogentec (Liege, Belgium). For antibody puriﬁcation, IgGs were
precipitated from serum with 50% (w/v) ammonium sulfate, redis-
solved in PBS and dialyzed against PBS. After depleting anti-GST-
IgGs with an excess of GST-Sepharose beads, anti-AIG30-12-1/
FBX33 IgGs were puriﬁed by GST-CT-Sepharose aﬃnity chromatog-
raphy. GST-CT-Sepharose columns were prepared by coupling the fu-
sion protein to BrCN activated Sepharose (Amersham) according to
the manufacturer’s instructions. Speciﬁc IgGs were eluted from the col-
umn with 0.1 M acetic acid/0.5 M NaCl, followed by an immediate
neutralization in 0.1 M Tris/HCl, pH 7.4. Puriﬁed IgGs were stabilized
in a 0.2% (w/v) BSA solution and dialyzed against PBS.
Antibodies against V5 (Invitrogen), HA (Roche), FLAG (Strata-
gene), Skp1 (Dianova), Roc1 (Neomarkers), Cul1 (Neomakers) and
tubulin (Dianova) were purchased from the commercial sources indi-
cated in parenthesis.
2.4. GST-pulldowns
The FBX33 cDNAs derived from pGEM-FL, pGEM-DN and
pGEM-DF were subcloned as BamHI fragments into pGEX4T1
(Amersham), as was the N-terminus (NT, aa 1–61) obtained from
pGEM-FL as a BamHI/Not1 fragment. The pGEX-FL, DN and DF
plasmids and the GST-fused YB-1 constructs [37] were transfected into
E. coli BL21(plysS) bacterial cells. Gene expression in bacteria was in-
duced by 0.2 mM isopropyl-b-D-thiogalactopyranoside and allowed to
proceed for 3 h at room temperature. Cells were harvested by centrifu-
gation and resuspended in lysis buﬀer consisting of 60 mM KCl,
20 mM HEPES, pH 7.8, 2 mM DTT, 1 mM EDTA, and 4 mg/ml lyso-
zyme. Cells were lysed by repeated freeze/thawing followed by sonica-
tion. After clearing the lysates of cell debris by centrifugation,
supernatants were gently mixed with glycerol and stored at 80 C
as 20% (v/v) glycerol stocks until use. GST fusion proteins were puri-
ﬁed with glutathione–Sepharose beads (Pharmacia) in NETN buﬀer
(20 mM Tris/HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5%
NP40, 1 mM DTT) for 30 min at room temperature under continuous
rotation. After repeated washings in NETN and adding of 200 lg of
BSA/sample, the beads were resuspended in 200 ll NETN containing
50 mg ethidium bromide and 3 ll of 35S labeled in vitro translated
YB-1. In vitro translation of YB-1 and FBX33 was performed using
the TNT coupled reticulocyte lysate system (Promega) according to
the manufacturer’s instructions. Binding reactions were supplemented
with 100 lg BSA and allowed to proceed for 60 min at room temper-
ature on a rotating device. After repeated washings in NETN, samples
were boiled in SDS-loading buﬀer and analyzed by SDS–PAGE.
2.5. Cell cultures and transfections
293 T cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(Gibco) supplemented with 10% (v/v) heat inactivated fetal calf serum
(Gibco) and 1% (v/v) penicillin–streptomycin–glutamine mix (Gibco).
Transfections were performed in presence of 25 lM chloroquine using
standard CaPO3 precipitation. After 16 h, the chloroquine was re-
moved and cells were allowed to grow in fresh medium for another
24 h.
To obtain a V5-tagged YB-1 expressing cell line 293T cells were
transfected with pcDNA6 V5 YB-1. After selecting for 2 weeks in Blas-
ticidin (5 lg/ml) individual cell lines were isolated and analysed for V5
YB-1 expression by Western blotting.
Luciferase activity in cell lysates was measured by using the dual-
luciferase reporter assay system (Promega) according to the manufac-
turer’s instructions.
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Transiently transfected 293T cells were washed in PBS and overlaid
with lysis buﬀer (50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 0.1% NP-
40, 10% glycerol, and 25 mM Na-b-glycerophosphate, 10 mM PMSF,
10 lg/ml aprotinin, 5 lM leupeptin, 10 mM Na3VO4, 10 mM NaF).
Lysates were cleared of cell debris by centrifugation. Antibodies (1–
2 lg/mg protein) were added to protein G Sepharose beads (Sigma)
precleared lysates and incubated at 4 C on a rotating device. After
12 h, lysates were again incubated for 4 h with protein G Sepharose
beads and then centrifuged for 2 min at 2000 · g. Pelleted beads were
washed, resuspended in SDS loading buﬀer and boiled prior to SDS–
PAGE and Western blotting.
2.7. In vitro ubiqitination assay
For in vitro YB-1 ubiquitination the Ubiquitin Protein Conjugation
kit (Boston Biochem) was used according to the manufacturers’
instructions. Brieﬂy, 0.5 ll of 35S labelled YB-1 was incubated in a
ubiquitination mix containing various amounts (i.e. 0.25, 0.5 and
1 ll) of in vitro translated full length (FL) or F-box-deleted (DFL)
FBX33. Similar amounts of empty expression vector served as negative
controls. Ubiquitination reactions were allowed to proceed for 4 h in
presence of 2 lM ubiquitin aldehyde after which the resulting products
were resolved by SDS–PAGE.
2.8. Northern blot analysis
Northern analysis of FBX33 transcription in FDCP-1 cells undergo-
ing apoptosis was performed as previously described [2]. Total RNA
from 293T cells was extracted in RNABee (TelTest) according to the
manufacturer’s instructions. RNAs were fractionated on 1.5% formal-
dehyde-agarose gels, blotted onto Nylon ﬁlters and hybridized to 32P-
labeled probes as previously described [2]. Blots were exposed to
PhosphorImager screens, scanned and quantiﬁed with the ImageQuant
software (Applied Biosystems). The hybridization probe for FBX33IL-3 withdrawal (h)0 41 8
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Fig. 1. Induction of AIG30-12-1 expression in FDCP-1 cells undergoing a
FDCP-1 cells at various intervals after IL-3 withdrawal was hybridized to 32P
alignment between the predicted AIG30-12-1 product and the human FBX3
(C) Detection of the AIG30-12-1 product in living cells. In vitro translation
total protein lysates from FDCP-1 cells were subjected to SDS–PAGE and
antibody.was generated by PCR using the following sequence speciﬁc primers:
FBX33: 5-TGATGAGCACTGGAAAGCC-3 0 and 5 0-TGATTCAA-
TGTCCAAGACTGC-30, GAPDH: 5 0-TTGAAGGGTGGAGC-
CAAACG-3 0 and 5 0-AGTGGATGCAGGGATGATGTTC-3 0.
Ampliﬁcation products puriﬁed from agarose gels were labeled by
random priming using the Rediprime II labeling kit (Amersham).3. Results
3.1. AIG30-12-1 encodes the mouse homolog of the hypothetical
FBX33
From a gene trap screen in FDCP-1 cells undergoing apop-
tosis by growth factor deprivation, we have isolated the
AIG30-12-1 [2]. As shown in Fig. 1A, a 4.1 kb AIG-30-12-1
transcript is induced in FDCP-1 cells shortly after IL-3 with-
drawal. Cloning and sequencing of this transcript revealed
an open reading frame for a protein of 562 aminoacids, which
is 93% identical to the hypothetical FBX33 (Fig. 1B) [3].
To test whether FBX33 is expressed from AIG30-12-1, we
raised polyclonal antibodies against the C-terminus of the
AIG30-12-1 translation product by immunizing rabbits with
GST fusion proteins produced in E. coli (see Section 2). As
shown in Fig. 1C (left lane), the aﬃnity puriﬁed monospeciﬁc
anti-AIG30-12-1 antibody detected an in vitro translation
product of 60 kDa on Western blots whose size corresponded
to the predicted FBX33 protein. A similar protein was identi-
ﬁed by the same antibody in FDCP-1 cells, indicating that an
FBX33-like protein is expressed in living cells (Fig. 1C, rightpoptosis. (A) Northern blot analysis. PolyA+ RNA recovered from
-labeled AIG30-12-1 and GAPDH speciﬁc probes. (B) Protein sequence
3 (GenBank Accession No. #NP_976046). F-Box residues are in bold.
(IVT) product of the AIG30-12-1 expression plasmid, pGEM-FL, and
analyzed by Western blotting using the polyclonal anti-AIG30-12-1
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M. Lutz et al. / FEBS Letters 580 (2006) 3921–3930 3925lane). However, the antibody also detected a smaller protein in
the FDCP-1 lysate, presumably corresponding to an alterna-
tive splice variant or a degradation product of FBX33
(Fig. 1C, right lane). Altogether, the results suggest that the
major protein translated from AIG30-12-1 is identical to the
hypothetical FBX33. Hence it will be referred to as FBX33
in the following sections.
3.2. FBX33 coprecipitates components of the SCF-complex
To investigate whether FBX33 is part of a multimeric SCF
ubiquitin ligase (E3) [38,39], the full length cDNA (FL) and
two N-terminal deletion mutants (DN and DF) were each
cloned in frame to an upstream hemagglutinine (HA) epitope
tag into a pcDNA3 expression vector (Fig. 2A). Epitope tag-
ging was necessary because the anti-AIG30-12-1 antibody
could not immunoprecipitate FBX33 from cell lysates. After
transient transfection in 293T cells, HA-tagged proteins and
complexes thereof were immunoprecipitated with anti-HA
antibodies from the cell lysates. Western blot analysis of theA
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methionine labeled FBX33. Binding was assessed as described in (B).immunoprecipitated complexes with antibodies against the
conserved SCF components revealed that both the full length
(FL) and the N-terminally truncated (DN) proteins coprecipi-
tated Skp1, Cul1 and Rbx/Roc1 (Fig. 2B). Interestingly, the
full length FBX33 precipitated Cul1 as a doublet in which
the higher molecular weight species is most likely a neddylated
form of Cul1 [40]. However, none of these proteins coprecipi-
tated with the F-Box deleted (DF) variant, indicating that the
F-Box mediates binding (Fig. 2B). Since FBX33 associates
with the SCF components in an F-Box dependent manner,
we conclude that FBX33 is a bona ﬁde F-Box protein.
3.3. FBX33 binds the transcription factor YB-1
To identify speciﬁc substrates for FBX33, we overexpressed
the HA-tagged full length (HA-FL) and F-Box deleted (HA-
DF) proteins in COS7 cells. Immunoprecipitates (IPs) obtained
from lysates with anti-HA antibodies were resolved by SDS–
PAGE and proteins that coprecipitated independently of the
F-Box were subjected to MALDI-TOF analysis. AmongGS
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3926 M. Lutz et al. / FEBS Letters 580 (2006) 3921–3930several proteins identiﬁed as potential substrates of FBX33
(i.e. karyopherin [importin] beta 3 [KPNB3], heat shock
90 kDa protein 1 beta [HSPCB], heat shock 70 kDa protein
9B [HSPA9B], DEAD box polypeptide 3 [DDX3X], nuclease
sensitive element binding protein 1/Y box binding protein-1
[NSEP1/YB-1], complement component 1/p32 [C1QBP]), the
transcription factor YB-1 was selected for further analysis.
To conﬁrm that FBX33 and YB-1 form a protein complex,
we coexpressed full length (HA-FL) FBX33 and V5 epitope-
tagged YB-1 (V5-YB-1) cDNAs in 293T cells. IPs obtained
from lysates (Fig. 3A) with either anti-HA (Fig. 3B) or anti-
V5 (Fig. 3C) antibodies were analyzed by Western blotting
using the same antibodies. As shown in Fig. 3B and C (lanes
7), V5-YB-1 was present in complexes precipitated by anti-
HA antibodies and, vice versa, HA-FL was present in com-
plexes precipitated by anti-V5 antibodies, indicating that
FBX33 and YB-1 bind to each other in a protein complex.
Since the majority of the functionally characterized FBPs re-
quire substrate phosphorylation prior to speciﬁc binding [5],
we tested whether the FBX33/YB-1 association is also depen-
dent on phosphorylation. Since treatment of the immunocom-
plexes with phophatases did not interfere with FBX33-YB-1
binding, we conclude that phosphorylation is not required
for this interaction (data not shown).
3.4. The amino-terminus of FBX33 is required for YB-1 binding
Initial MALDI-TOF analysis revealed that an N-terminally
truncated form of FBX33 cannot bind to YB-1 (data not
shown). This observation was surprising, as most FBPs useIP: HA
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Fig. 5. Coprecipitation of SCF components by YB-1. 293T cells were tran
expressing constructs in the combinations indicated on the top. Crude pr
analyzed by Western blotting using anti-HA, -FLAG, -Skp1 and -Cul1 an
proteins are marked by arrows. HA, pcDNA6- expression vector; FLAG, pCM
F-Box deleted FBX33.their C-terminus for speciﬁc substrate binding [7], and
prompted us to investigate whether FBX33 binds YB-1 via
its N-terminus. Towards this end, we fused the full length
(FL), the N-terminally deleted (DN), and an N-terminus only
encoding (NT) cDNA to GST and expressed the fusions in
E. coli (Fig. 4A). GST aﬃnity puriﬁed fusion proteins were
then added to in vitro translated, 35S-methionine labeled YB-
1. Fig. 4B (lanes 3 and 5) shows YB-1 binding to GST-FL
and GST-NT but not to GST-DN (lane 4), suggesting that
the N-terminus of FBX33 is both required and suﬃcient for
YB-1 binding.
3.5. FBX33 binds to the CSD of YB1
To map the FBX33 binding site in YB1, we expressed the
YB-1 deletion mutants shown in Fig. 4C (top) in E. coli.
GST aﬃnity puriﬁed fusion proteins were then added to
in vitro translated, 35S-methionine labeled FBX33. Fig. 4D
shows that only the GST-D3 mutant lacking the CSD failed
to bind FBX33 (lane 6) and that the CSD (GST-D5) alone
was suﬃcient for binding (lane 8). Together, these results indi-
cate that the N-terminus of FBX33 speciﬁcally associates with
the CSD of YB-1.
3.6. FBX33 recruits Skp-1/Cul1 to YB-1
As part of a SCF-E3 ubiqitin ligase (SCFFBX33), FBX33
should recruit the conserved SCF components to its substrate.
To test this, we expressed a HA-tagged YB-1 (HA-YB-1) with
FLAG tagged full length (FLAG-FL) or FLAG tagged F-Box
deleted (FLAG-DF) FBX33 in 293T cells. When IPs obtained-Y
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Skp1 or anti-Cul1 antibodies on Western blots, HA-YB-1
complexes containing the full length FBX33 (FLAG-FL) read-
ily coprecipitated endogenous Skp1 and Cul1 (Fig. 5, lane 7),
indicating their recruitment to the substrate. As expected,
recruitment was depended on the F-Box, as neither Skp1 nor
Cul1 coprecipitated with the F-Box-deleted variant (FLAG-
DF) of FBX33 (Fig. 5, lane 8).
3.7. YB-1 is polyubiquitinated and degraded by the proteasome
The existence of an SCFFBX33 with substrate speciﬁcity for
YB-1 implies that YB-1 is polyubiquitinated and degraded
by the proteasome. We veriﬁed this assumption in two sets
of experiments. First, we tested whether ubiquitin binds to
YB-1 after cotransfecting V5-YB-1 and HA tagged-ubiquitin
expression plasmids into 293T cells. Fig. 6A shows that ubiq-
uitin containing complexes precipitated from lysates with anti-
HA antibodies included V5-YB-1. Moreover, the amount ofanti-V5-Y
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Fig. 6. Polyubiquitination and proteasomal degradation of YB-1. (A) Dose
ubiquitin. 293T cells were transfected with 2.5 lg empty (control) or V5-YB1e
5 lg HA-ubiquitin expression plasmid. Immunoprecipitates obtained from ly
anti-V5 antibodies. (B) V5-YB-1 degradation in presence or absence of the pro
293T cells were treated with actinomycin D (10 lg/ml) and analyzed by We
ubiquitination of YB-1 by SCFFBX33 complexes. Right panel: 35S-labeled YB
translated full length (FL), F-Box deleted (DF) or no (pGEM) FBX33. Polyu
autoradiography. Left panel: in vitro control ubiquitination of 35S-labeled Yubiquitin conjugated YB-1 increased with ubiquitin expression
(Fig. 6A, lanes 5 and 6), indicating that YB-1 is polyubiquiti-
nated. Second, we determined whether YB-1 is degraded by
the proteasome by measuring the rate of its decay in the pres-
ence of proteasome inhibitors. As shown in Fig. 6B, the V5-
YB-1 levels in overexpressing 293T cells progressively declined
after blocking gene transcription with actinomycin D. How-
ever, this process was readily reversed by the proteasome
inhibitors – Clasto-Lactacystin and MG132 (Fig. 6B), indicat-
ing that the proteasome is required for degradation. We con-
clude from these results that YB-1 is catabolized by the
ubiquitin-proteasomal pathway.
3.8. FBX33 targets YB-1 for ubiquitination
To test whether SCFFBX33 mediates in vitro ubiquitination
of YB-1, we incubated 35S-labeled YB-1 with in vitro trans-
lated full length (FL) or F-Box deleted (DF) FBX33 and esti-
mated the degree of YB-1 ubiquitination using SDS–PAGE.B-1
ulin
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sates with anti-HA antibodies were analyzed by Western blotting using
teasome inhibitors Clasto-Lactacystin or MG132. V5-YB-1 expressing
stern blotting using anti-V5- and anti-tubulin antibodies. (C) In vitro
-1 was incubated with an ubiquitination mix containing cold in vitro
biquitinated products were resolved by SDS–PAGE and visualized by
B-1 in presence (+Ub) or absence (Ub) of ubiqutin.
3928 M. Lutz et al. / FEBS Letters 580 (2006) 3921–3930Fig. 6C (right panel) shows that FBX33 signiﬁcantly enhances
YB-1 polyubiquitination in a dose dependent manner (lanes 4–
6); an eﬀect that was not observed with the F-Box deleted (DF)
variant (lanes 7–9) or in the absence of ubiquitin (Fig. 6C, left
panel). This strongly suggests that the SCFFBX33 is a speciﬁc
E3-ubiquitin ligase for YB-1.
3.9. FBX33 enhances the proteasomal degradation of YB-1 in
living cells
To investigate whether FBX33 can directly induce proteaso-
mal YB-1 degradation in living cells, we transiently expressed
the full length (FLAG-FL) and the F-Box deleted (FLAG-DF)
protein in a V5-YB-1 expressing (293T) cell line. Fig. 7A shows
that the steady state V5-YB1 levels are reduced by FBX33 in a
dose and F-Box dependent manner. Moreover, in the same
cells treated with actinomycin D, FBX33 accelerated the pro-
teasomal degradation of residual V5-YB-1, conﬁrming that
YB-1 is a substrate for the SCFFBX33 ubiquitin ligase
(Fig. 7B, C). This process could be readily reversed by the pro-FL
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plasmids. Transfection of 2 lg of empty expression vector (FLAG) served as
anti-V5 and anti-FLAG antibodies. (B) YB-1 half-life reduction by FBX33. V
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actinomycin D treatment (10 lg/ml) using anti-V5 and anti-tubulin antibodie
mediated by endogenous FBX33, which is expressed in 293T cells (data not
intensities were quantiﬁed from Western blots derived from experiments sim
against time. Data points were normalized to the ‘‘0’’ time point and are me
mediated YB-1 degradation by the proteasome inhibitor MG132. Cells were t
presence or absence of MG132. Cell lysates were analyzed by Western blottteasome inhibitor MG132, indicating that YB-1 degradation is
dependent on the proteasome (Fig. 7D, lanes 1, 2 and 3).
3.10. FBX33 represses YB-1 transactivation
By reducing the intracellular levels of YB-1, FBX33 is likely
to negatively interfere with YB-1 mediated functions. To inves-
tigate this, we transfected 293T cells with the YB-1 inducible
luciferase expression plasmid pALUC [26]. As shown in
Fig. 8, the transfected 293T cells expressed high basal levels
of luciferase, suggesting high endogenous YB-1 expression.
In line with this, we were unable to further induce luciferase
expression by expressing exogenous YB-1 (data not shown).
However, expression of the full length (FLAG-FL) but not
of the F-Box deleted variant (FLAG-DF) of FBX33 signiﬁ-
cantly reduced the luciferase levels in a dose-dependent man-
ner (Fig. 8A), and this process could be reversed by
coexpressing exogenous YB-1 (Fig. 8B). Thus, the SCFFBX33
complex negatively interferes with YB-1 regulated gene
expression.FLAG
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Fig. 8. Repression of YB-1 transactivation by FBX33. (A) Luciferase
activity in 293T cells transfected with the reporter plasmid pALUC
(0.2 lg) in combination with variable amounts of FLAG tagged-
FBX33 expression vectors. Results are means ± S.D. of three inde-
pendent experiments. *P = 0.05, **P = 0.035, ***P = 0.026; #P > 0.1
(Student’s t-test compared to empty vector). For (B) Luciferase activity
in pALUC and pFLAG-FBX33 (1 lg) transfected 293T cells after
cotransfecting pV5-YB-1. Results are means ± S.D. of three indepen-
dent experiments. *P = 0.008, **P = 0.009, #P = 0.49 (Student’s t-test
compared to empty vector). V = pCMVTag4A expression vector,
FLAG-FL, full length FBX33; FLAG-DF, F-Box deleted FBX33; V5,
pcDNA6 expression vector.
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By using a gene trap strategy that selects for genes induced
during PCD, we have isolated a cDNA coding for the hypo-
thetical FBX33. We have shown that FBX33 is part of a mam-
malian SCF-E3 ubquitin ligase that targets the multifunctional
regulator YB-1 for proteasomal degradation and thereby neg-
atively interferes with YB-1 transactivation.
FBPs were originally discovered in yeast and shown to play
a crucial role in cell cycle control [38,39]. Homologs have been
identiﬁed in several other species, and with assistance from sev-
eral completed genome sequences, a growing number of FBPs
are being identiﬁed in various organisms [3,9,41,42]. However,
the prevailing paradigm of an SCF complex – where the F-Box
motif is required to tether a substrate to the complex for ubiq-
uitination – has been veriﬁed only for a minority of FBPs. Fur-
ther, only for a very few of these, the substrate binding
speciﬁcities are known.
In this context, it is important to point out that the func-
tional topology of SCF complexes was essentially established
in studies of two prototypes: the human SCFSkp2 and the yeast
SCFCdc4, which are both involved in cell cycle control[38,39,43]. While the F-Box motif in the F-Box protein Skp2
binds Skp1, the leucine rich, C-terminal LRR domain binds
the Cdk2 inhibitor – p27Kip1 – as its speciﬁc substrate [44].
Similarly, the Cdc4 protein from the related yeast SCF also
binds a Cdk inhibitor but uses instead a C-terminal WD40 do-
main [45]. Although other protein interaction domains exist in
several FBPs and may suggest additional functions, only the
LLR and WD40 domains have been shown experimentally
to bind speciﬁc substrates [5]. To our knowledge YB-1 is the
ﬁrst example of an ubiquitination target for an F-Box protein
that has no obvious protein interaction domains outside the F-
Box, and FBX33 is the ﬁrst example of an F-Box protein that
binds its substrate via the N-terminus. Moreover, unlike the
FBPs in the SCF prototypes and related complexes
[5,38,39,43], FBX33 binds YB-1 without requiring its prior
phosphorylation.
Although cell cycle regulators have been the major focus of
SCF complex related studies, FBPs can target a variety of non-
cell cycle related proteins, including cytoskeletal regulators,
signal transducers, transcription factor inhibitors, and tran-
scription factors such as YB-1. Many FBPs have multiple
ubiquitination targets and often exhibit additional functions
unrelated to the proteasomal pathway (reviewed in [46]). For
example, FBPs can act as enzymes, transcriptional enhancers
or intracellular protein transporters [47–49]. Therefore, it will
be important to determine whether FBX33 has other ubiquiti-
nation targets and/or functions that are unrelated to ubiquiti-
nation.
In conclusion, the present study conﬁrmed the existence of
the formerly hypothetical FBX33 as an SCF complex in living
cells and identiﬁed YB-1 as one of its speciﬁc ubiquitination
targets.
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